Navigation Links
Researchers reveal potential treatment for sickle cell disease
Date:11/1/2011

Ann Arbor, Mich. -- A University of Michigan Health System laboratory study reveals a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease.

The study, conducted in mice, appears in this week's early edition of the Proceedings of the National Academy of Sciences, and holds promise for preventing the painful episodes and organ damage that are common complications of sickle cell disease.

According to the U-M study, increasing the expression of the proteins, TR2 and TR4, more than doubled the level of fetal hemoglobin produced in sickle cell mice and reduced organ damage.

It's the first time specific proteins have been targeted to prevent a disease, authors say.

"The vast majority of sickle cell disease patients are diagnosed early in childhood when adult hemoglobin normally replaces fetal hemoglobin, but the severity of the disease can differ markedly, correlating most strongly with the level of fetal hemoglobin present in red cells," says pediatrician and lead study author Andrew D. Campbell, M.D., director of the Pediatric Comprehensive Sickle Cell Program at the U-M Cancer Center.

Sickle cell is an inherited blood disorder impacting hundreds of thousands of patients worldwide that causes normal red blood cells to change shape to a crescent moon.

The result is life-long debilitating pain episodes, chronic organ damage and significantly shortened life span. But a small number of sickle cell patients are born with a high enough fetal hemoglobin level to moderate these complications.

The study team, that included pediatric hematologists, cell and developmental biologists and pathology experts at U-M and the University of Tsukuba, Japan, demonstrated a potential method for boosting the fetal hemoglobin levels by modulating TR2/TR4 expression.

"While the average fetal hemoglobin was 7.6 percent in the sickle cell mice, the TR2/TR4 treated sickle cell mice had an average fetal hemoglobin of 18.6 percent," says senior study author James Douglas Engel, Ph.D. , professor and chair of the U-M's Cell and Development Biology Department.

He adds that anemia and red blood cell turnover all improved within the TR2/TR4 mice. Additional studies, including clinical trials, would be requiredto determine if the technique could help humans.

"Currently hydroxyurea is the only FDA approved drug known to increase the levels of fetal hemoglobin within sickle cell disease patients and a substantial number of patients do respond to it," says Campbell, the pediatric hematology oncology specialist. "But the long term consequences for hydroxyurea are unknown, especially in children."


'/>"/>
Contact: Shantell M. Kirkendoll
smkirk@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Senior citizens as co-researchers to improve urban planning
2. Plant researchers locate transporter used for nicotine metabolism
3. Live-action films of worm sperm help researchers track critical fertility enzymes
4. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
5. Researchers identify potential risk factors for severe altitude sickness
6. Moffitt Cancer Center researchers find more clues to causes of breast cancer
7. Georgetown researchers examine 21-year series of nipple sparing mastectomy cases and find no cancers
8. Medical researchers ID potential new drug target that could stop debilitating effects of MS
9. Researchers develop method to better estimate vaccine coverage
10. Veterinary researchers discover first US strains of hepatitis E virus from rabbits
11. Researchers have found evidence for the existence of a hypnotic state
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Researchers reveal potential treatment for sickle cell disease
(Date:7/25/2017)... Jacksonville, Fla. (PRWEB) , ... July 25, 2017 , ... ... employee and father Ezra Clark is taking advantage of a new benefit for employees ... “It really means a lot that the company supports me and other employees as ...
(Date:7/25/2017)... ... July 25, 2017 , ... SignatureCare Emergency Center – South ... TX area 24 Hours a day. , The Emergency Room opened ... “We’ve been open four months now and things are running smoothly,” said Aaron Braun, ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... , Robins & Morton, Perkins Will, Newcomb & Boyd, Walter P Moore ... the new Destination Medical Building located at Mayo Clinic in Jacksonville, Florida. ...
(Date:7/24/2017)... ... July 24, 2017 , ... SignatureCare Emergency Center is looking to ... fall semester to a deserving student. Get your applications in now as the ... to Mariana Castillo who is a nursing student at Prairie View A&M University with ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to the Opioid ... Health Care Services, will facilitate the development of a hub and spoke model ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Dr. Echenberg, founder of Echenberg Institute, is announcing a new safe and ... painful intercourse and other painful pelvic pain conditions such as pelvic floor ... ... ... -based start-up company, VuVatech LLC, fills a void in the women,s ...
(Date:7/10/2017)... , July 10, 2017  US medical equipment ... in 2021, according to Medical Equipment & ... by Freedonia Focus Reports. Continued increases in demand for ... aging of the population and supported by gains in ... equipment and supplies. New product introductions will also drive ...
(Date:7/10/2017)... , July 10, 2017  BDI Group subsidiary ... patient support services organization serving specialty pharmacies, home ... launch of four significant, value-added member programs designed ... better manage reimbursement and improve access and affordability ... therapies. ...
Breaking Medicine Technology: